A retrospective review in the management of T3 laryngeal squamous cell carcinoma: an expanding indication for transoral laser microsurgery by unknown
ORIGINAL RESEARCH ARTICLE Open Access
A retrospective review in the management
of T3 laryngeal squamous cell carcinoma:
an expanding indication for transoral laser
microsurgery
A. Butler*, M. H. Rigby, J. Scott, J. Trites, R. Hart and S. M. Taylor
Abstract
Background: The purpose of this study was to evaluate the functional and oncological outcomes of patients treated
for T3 laryngeal squamous cell carcinoma. Specifically comparing transoral laser microsurgery and radiotherapy/
chemoradiotherapy treatment modalities.
Method: A retrospective review of patients treated for T3 laryngeal SCC between 2002 and 2010 was undertaken.
Results: Forty-nine patients were included. 15 cases were glottic, (9 treated with TLM, 6 with RT/CRT), 33 supraglottic
(6 treated with TLM, 27 with RT/CRT) and 1 subglottic subsite (treated with RT/CRT). There was no statistical difference
between treatment groups for 24 month locoregional control (72.3 %), overall survival (glottis 86.7 %, supraglottic 70.
4 %) and disease specific survival (glottic 93.3 % and supraglottic 74.1 %). Overall laryngeal preservation (84.9 %) was
also similar in both groups.
Conclusion: Our institution is expanding the application of TLM to selected patients with T3 laryngeal carcinoma.
Oncological outcomes have not been jeopardized by this approach and the treatment is well tolerated by patients
with few complications.
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Background
Laryngeal cancer is the second most frequent head and
neck cancer. The overwhelming majority of these can-
cers are squamous cell carcinomas. These cancers are
associated with both tobacco and alcohol use and, while
this is changing, have historically occurred predomin-
antly in males. For the 2010 Canadian population, laryn-
geal cancer had an estimated incidence rate of 2.0/100
000 person*years for males and 0.9/100 000 person*years
in females [1]. U.S data has demonstrated that over the
past 30 years, laryngeal cancer has the distinction of be-
ing one of the few cancers of the head and neck that has
shown a decrease in survival [2, 3].
Transoral laser microsurgery (TLM), originally intro-
duced in 1972 by Jako and Strong [1], has consistently
been shown to have good oncological and functional
outcomes in patients with early glottic cancer. Steiner et
al,. reported oncological and functional results in the
treatment of T3 laryngeal tumours equivalent to radio-
therapy (RT)/chemoradiotherapy(CRT) and open laryn-
geal surgery, which expanded the indications for TLM in
laryngeal cancer [2]. Despite this, the management of T3
glottic carcinoma remains controversial. Most com-
monly, such tumours are treated with radical radiother-
apy with adjuvant chemotherapy, open partial resection,
or total laryngectomy.
Although recent studies support a possible role for a
primary surgical approach, few centers such as the
QEII Health Sciences Centre in Halifax, Nova Scotia
have incorporated the use of TLM in the management
of T3 glottic tumours [2]. The purpose of this paper is
to review all T3 laryngeal squamous cell carcinomas
(SCC) treated at the QEII Health Sciences Centre in
Halifax, Nova Scotia, and to compare those patients* Correspondence: drangelabutler@gmail.com
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treated with TLM to those managed with radiotherapy/
chemoradiotherapy.
Method
Data was obtained from the senior authors prospective
database of malignancies treated with TLM at the QEII
Health Sciences Centre in Halifax, Nova Scotia. Our in-
stitutional research ethics board approved the collection
of information within the database. The details of this
database have been previously described [4]. It has been
prospectively maintained since 2005, and data prior to
2005 included retrospectively.
Inclusion criteria included all patients who underwent
TLM or RT/CRT with curative intent for previously
untreated T3 laryngeal SCC between January 2002 and
December 2010. Exclusion criteria included all other
sub-sites and stages, and recurrent T3 glottic SCC.
A retrospective cohort analysis was performed includ-
ing a descriptive analysis of demographics and onco-
logical outcomes. Demographics recorded included age,
gender and smoking status. ANOVA test for difference
in means and the Fisher Exact test were performed to
identify any differences between the two therapeutic
groups. Tumours were staged according to TNM Ameri-
can Joint Committee on Cancer (AJCC) guidelines [5].
Tumours excised with TLM were staged pathologically.
Treatment modality and date of treatment commence-
ment were recorded. Any treatment morbidity or com-
plications were identified. Survival analysis using Kaplan
Meier curve was performed, assessing local, regional and
distant metastatic control, disease free survival, disease
specific survival, overall survival and laryngeal preserva-
tion. Two year outcomes were recorded as 5 year data
was not yet available.
All patients were treated with either transoral laser
microsurgery +/- adjunctive radiation therapy (TLM),
chemoradiation (CRT) or radiation therapy (RT) alone.
Allocation to treatment modality was not randomized
and was based on patient preference and recommenda-
tion of the site Head and Neck Oncology Tumour
Board. Not all patients were considered eligible for all
treatment modalities. Patients undergoing radiation alone
either refused chemotherapy, or had a medical contraindi-
cation. Transoral laser surgery was performed using a
tumour splitting technique with a CO2 laser. Frozen sec-
tions were performed intraoperatively, and positive mar-
gins post-operatively were re-resected. Radiation therapy
was performed using intensity modulated radiation ther-
apy with 70 Gy with standard fractionation. Concurrent
chemotherapy consisted of Cisplatinum with or without
5-fluorouracil given on weeks 1, 4 and 7 concurrently with
radiation.
Functional outcomes of voice and swallowing were
documented as assessed at the last follow up review,
using Voice Handicap Index (VHI) 10 and Functional
Outcome Swallowing Study (FOSS) respectively. No
scores were available prior to treatment commencement.
Results were analysed using the Wilcoxon significance
rank test.
Results
Forty-nine patients met the inclusion criteria of the
study. Fifteen (30.6 %) were treated with TLM and the
remaining 34 (69.4 %) were treated with RT/CRT. No
patients underwent open laryngeal surgery for primary
treatment. 15 cases were glottic, (9 treated with TLM, 6
with RT/CRT), 33 supraglottic (6 treated with TLM, 27
with RT/CRT) and 1 subglottic subsite (treated with RT/
CRT). Table 1.
Thirty-eight patients (77.6 %) were male, with no dif-
ference in gender distribution between the two treat-
ment groups (p-value 0.5). The mean age was 69.1 years
(61.1 years TLM, 66.5 years RT/CRT, age difference be-
tween treatment groups p value 0.39). Mean follow-up
duration for those treated with TLM was 29 months,
and 41 months for those treated with RT/CRT. Thirty-
three patients were staged as N0, eight as N1 and eight
as N2. No patients presented with distant metastasis.
The majority of patients with nodal metastasis received
RT/CRT (17) as primary treatment rather than TLM (3).
Seven (46.7 %) of TLM patients underwent adjuvant RT.
None received adjuvant chemotherapy. Twenty-four
(77.4 %) patients who underwent RT received concur-
rent chemotherapy. There were no statistically signifi-
cant differences in the parameters of age, gender,
smoking status, nodal status and date of initial treatment
between treatment modalities. Table 2.
Locoregional control
Thirteen patients in the study group developed a locore-
gional recurrence (26.5 %). The Kaplan-Meier estimates
for 24 month locoregional control was 72.3 % in the en-
tire cohort. There was no difference between the treat-
ment groups (72 % TLM, 71.6 % RT/CRT p value 0.94)
Fig. 1.
In patients with glottic cancer, the Kaplan Meier esti-
mate for locoregional control was 86.7 %. Two patients
in the glottic group developed locoregional recurrence
(12.5 %). Although they were both treated with TLM,
this was not statistically significant compared to those
Table 1 Treatment according to subsite
Primary treatment modality TLM RT Total
Adjuvent treatment RT CT CT
Glottic 9 4 0 6 4 15
Supraglottic 6 3 2 27 20 33
Subglottic 1 1
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treated with RT/CRT (p value 0.98) Both patients were
managed with a salvage laryngectomy.
The Kaplan Meier estimate for locoregional control in
patients with supraglottic cancer was 64.5 %, with no sta-
tistically significant difference between treatment groups
(p value 0.98). Of the 11 patients (33.3 %) with recurrence,
2 were treated with TLM (33.3 %) and 9 with RT/CRT
(33.3 %). Both patients treated with TLM who developed
recurrence, were successfully treated with subsequent
radiotherapy. Those patients with recurrence treated ini-
tially with RT/CRT, 2 were managed successfully with
TLM, 1 was treated palliatively, and the remaining pa-
tients underwent salvage total laryngectomy.
Survival
Of the 49 patients, 12 (24.5 %) died within 24 months. Of
these, 9(18.3 %) deaths were disease-related. Kaplan-Meier
estimates showed 2 year overall survival was 75 % and
again similar between the two treatment groups with
73.3 %% in the TLM group and 75.8 % RT/CRT group (p
value 0.8) Fig. 2. Glottic overall survival was 86.7 % while
supraglottic overall survival was 70.4 %. Neither group
showed a statistical difference between treatment regimens.
Overall disease specific survival was 81.4 % and was
also similar for those treated with TLM (86.2 %), and
those treated with RT/CRT (79.4), (p value 0.60) Fig. 3.
Glottic DSS was 93.3 % and supraglottic DSS was
74.1 %. Again neither group showed a statistically signifi-
cant difference between treatment regimens (p value
0.41 and 0.75 respectively).
Laryngeal preservation
Overall laryngeal preservation rates (84.9 %) trended to-
wards being greater in the TLM group (93 vs 81 %), but
this was not statistically significant. (p value 0.35) Fig. 4.
Table 2 Patient age, gender, nodal staging, smoking status and
date of treatment according to treatment
All TLM RT CRT p
Number 49 15 10 24 -
Age 0.39a
Mean 63.1 61.1 66.5 63.0
(SD) (9.6) (11.2) (7.5) (9.4)
Gender 0.50b
Female 11 3 1 7
Male 38 12 9 17
(% Male) (78 %) (80 %) (90 %) (71 %)
Nodal stage 0.36b
0–I 41 14 9 18
II–III 8 1 1 6
(%II–III) (16 %) (7 %) (10 %) (25 %)
Smoking 0.67b
No 16 5 5 7
Yes 10 4 1 5
Unknown 23 6 4 12
(% Yesc) (37 %) (44 %) (17 %) (42 %)
Date of initial treatment 0.30b
2002–06 24 5 5 14
2007–11 25 10 5 10
(% 2007–11) (51 %) (67 %) (50 %) (42 %)
aANOVA F-test for means TLM, RT, CRT
bFisher exact test for table TLM, RT, CRT
c% of those with known smoking status
Fig. 2 Two-year Kaplan-Meier estimates for overall survival (TLM 73.3 %,
RT/CRT 75.8 %, p value 0.8)
Fig. 1 Two-year Kaplan-Meier estimates for overall locoregional control
(72.3 %, no difference between either treatment group, p value 0.94))
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Glottic laryngeal preservation was 86.7 % and supraglot-
tic laryngeal preservation 83.9 %. Although there was
not a statistical difference between TLM and RT/CRT in
either subsite, it is worth noting that no patients treated
with TLM in the supraglottic group required a salvage
laryngectomy.
Post-operative complications and functional results
Voice Handicap Index (VHI) and Functional Outcome
Swallow Scale (FOSS) scores were available in only a
limited number of patients. For glottic cases, the median
function outcomes at last post-treatment visit trended
towards worse voice scores (VHI 10) for those treated
with TLM (15 TLM, 11 RT/CRT) but this was not statisti-
cally significant. However, for supraglottic cases, VHI
trended towards better in those treated with TLM (9
TLM, 11.5 RT/CRT). Median FOSS scores were identical.
In the TLM glottic group one patient developed a
small post-operative hemorrhage, which did not require
any intervention. No patients required temporary or per-
manent tracheostomy, and none required nasogastric
feeding. One patient in the RT/CRT group required
nasogastric nutrition and three patients were unable to
tolerate chemotherapy and the treatment discontinued.
Discussion
Following the Department of Veterans Affairs Laryngeal
Cancer Group trial the management of laryngeal cancer
shifted towards chemoradiation [6]. During the 1990’s it
was noted by Hoffman et al. that with the increased use
of CRT, the 5-year survival for T3N0M0 laryngeal cancer
had declined [7]. More recently, there continues to be
much debate regarding best treatment practices for ad-
vanced laryngeal tumours, in particular a move back to-
wards primary surgical treatment.
Total laryngectomy (TL) is frequently used to treat T3
glottic carcinoma with or without (chemo) radiotherapy.
Although good oncological results are achieved with TL,
the operation has obvious functional sequelae. Published
5-year locoregional control and overall survival range
from 69 to 87 % and 53 to 56 % respectively [8–10].
Open partial laryngectomy also has good locoregional
control and overall survival with 5-year rates between 73
and 83 % and 71 to75% respectively [11, 12]. In this
study, our locoregional control and overall survival for
T3 glottic carcinomas treated with TLM are similar to
that of open laryngeal procedures, with locoregional
control of 87 % and 2 year overall survival of 68 %.
Radiotherapy alone in the absence of chemotherapy
has been shown to have poorer outcomes. Chemother-
apy, however, is contraindicated in patients with poorer
general health. In patients who therefore have a
favourable tumour location, yet in whom chemotherapy
is a contraindication, TLM is without question a reason-
able surgical option.
As this was not a randomized study, those patients se-
lected for TLM may have had favourable anatomy and
tumour location. Because of this fact, a direct compari-
son of the two groups should be interpreted cautiously.
However, management with TLM did not appear to
jeopardize oncological outcomes in those selected for
this minimally invasive approach.
The low numbers within groups make the study
underpowered to detect clinically significant differences
between treatments. However, adequate sample size for
this study to power the log rank test this to be able to
detect the difference between a 5-year survival of 0.8 to
Fig. 3 Two-year Kaplan-Meier estimates for overall disease specific
survival (81.4 %, no difference between either treatment group,
p value 0.60)
Fig. 4 Two-year Kaplan-Meier estimates for overall laryngeal preservation
(84.9 %, no difference between either treatment group, p value 0.35)
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0.7 are would require over 1000 cases, and would be dif-
ficult to obtain this sample size outside of a national
database.
The cases in this trial were not selected for treatment
by patient and tumour characteristics and were not ran-
domized. There are two potential differences in the char-
acteristics of persons between treatment modalities that,
while not statistically significant, are concerning with re-
spect to the comparability of treatment groups. The first
is the increased mean age of those undergoing radiation
therapy alone. This would be expected as age greater
then 70–75 is a relative contraindication to CRT. This is
the cutoff that has been excluded from most CRT trials,
and there is a higher rate of significant morbidity associ-
ated with CRT in those over 70–75. The second is the
fact that 75 % of all N2 and N3 disease was treated by
CRT. N2 or N3 disease upstages T3 laryngeal cancer to
stage IVa and IVb respectively. This relative overrepre-
sentation of more advanced disease in the CRT group
may underestimate the efficacy of this modality when
compared to TLM and RT groups.
Although this study showed reasonably low complica-
tion rates in those receiving chemoradiotherapy, chemo-
therapy in addition to the radiotherapy is known to have
associated significant toxicity with mucositis, leukopenia
and a 2 % increase in early deaths secondary to acute tox-
icity [13–15]. As complications were not prospectively re-
corded, mucositis and leukopenia were not accurately
documented in this study and it is likely that compared to
surgical complications, they were underreported.
When locoregional recurrence does occur in patients
treated with TLM, options for management include fur-
ther TLM, RT/CRT or open partial or total laryngec-
tomy. For patients treated primarily with RT/CRT,
although salvage surgery is possible the rate of complica-
tions in particular pharyngocutaneous fistula, the need
for microvascular or regional flaps, complexity of sur-
gery and the overall cost of prolonged hospital stay sig-
nificantly increase [16, 17]. Complications of salvage
treatment were not specifically reviewed in this study.
Anecdotal evidence suggests complications from sal-
vage surgery are likely to be less if radiotherapy can
be avoided.
Over the study period, the senior authors selection of
patients for TLM has changed. As surgical experience in
TLM increased for early glottic carcinoma and expertise
has developed, so too was there an increase in the T3
cases treated with TLM. Bernal-Sorekelsen et al. re-
ported that for locally advanced tumours, a significant
difference in the experience of the surgeon altered the
complication rate, in particular bleeding and aspiration
pneumonia [18]. They recommended for TLM “begin-
ners” even when experienced in external approaches, to
accumulate a significant experience with early staged
tumors before attempting to treat advanced cases in this
manner.
It has been the experience of the senior author, and
also discussed in the literature, that T3 glottic tumours
with vocal cord fixation are more likely to develop local
recurrence [19]. Cord fixation may be due to a number
of factors, including cricoarytenoid joint involvement,
muscle infiltration or paraglottic space involvement.
Whilst true cord fixation is both a poorer prognostic fac-
tor for TLM and more likely to result in post-operative
aspiration, paraglottic involvement does not carry such a
poor prognosis. Therefore careful pre-operative image
review and clinical assessment of the patient is impera-
tive. As noted by Vilaseca et all, pre-epiglottic space in-
volvement is associated with a better prognosis for
TLM, as the pre-epiglottic space can be easily exposed
and wider margins achieved with good functional out-
comes. It is our opinion that the same can be said for
isolated paraglottic space invasion in T3 glottic cancer.
Conclusion
The use of transoral laser microsurgery for advanced la-
ryngeal cancer is controversial. With over a decade of in-
creasing experience with TLM for early glottic cancer,
our institution is expanding the application of TLM to
selected T3 glottic carcinoma. Oncological outcomes are
not jeopardized by this approach and the treatment is
well tolerated by patients with few complications. The
data reported herein supports the ongoing use of TLM
for selected T3 glottic cancers at our centre.
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